SE0103644D0 - Therapeutic isoquinoline compounds - Google Patents

Therapeutic isoquinoline compounds

Info

Publication number
SE0103644D0
SE0103644D0 SE0103644A SE0103644A SE0103644D0 SE 0103644 D0 SE0103644 D0 SE 0103644D0 SE 0103644 A SE0103644 A SE 0103644A SE 0103644 A SE0103644 A SE 0103644A SE 0103644 D0 SE0103644 D0 SE 0103644D0
Authority
SE
Sweden
Prior art keywords
disorders
sub
compounds
therapeutic
isoquinoline compounds
Prior art date
Application number
SE0103644A
Other languages
English (en)
Inventor
Edward Pierson
Ashokkumar Shenvi
Markus Haeberlein
Gary Moore
Daniel Hill
Robert Jacobs
Cristof Angst
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103644A priority Critical patent/SE0103644D0/sv
Publication of SE0103644D0 publication Critical patent/SE0103644D0/sv
Priority to HU0501089A priority patent/HUP0501089A2/hu
Priority to IL16151102A priority patent/IL161511A0/xx
Priority to CA002464342A priority patent/CA2464342A1/en
Priority to JP2003540168A priority patent/JP2005516896A/ja
Priority to US10/494,424 priority patent/US20070010526A1/en
Priority to MXPA04004076A priority patent/MXPA04004076A/es
Priority to RU2004112423/04A priority patent/RU2004112423A/ru
Priority to PL02370058A priority patent/PL370058A1/xx
Priority to EP02780244A priority patent/EP1451172A1/en
Priority to CNA028262816A priority patent/CN1608061A/zh
Priority to KR1020047006593A priority patent/KR20050042223A/ko
Priority to BR0213778-0A priority patent/BR0213778A/pt
Priority to PCT/SE2002/001988 priority patent/WO2003037887A1/en
Priority to IS7236A priority patent/IS7236A/is
Priority to ZA200403240A priority patent/ZA200403240B/en
Priority to CO04039910A priority patent/CO5580832A2/es
Priority to NO20042154A priority patent/NO20042154L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SE0103644A 2001-11-01 2001-11-01 Therapeutic isoquinoline compounds SE0103644D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0103644A SE0103644D0 (sv) 2001-11-01 2001-11-01 Therapeutic isoquinoline compounds
PCT/SE2002/001988 WO2003037887A1 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
PL02370058A PL370058A1 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
CNA028262816A CN1608061A (zh) 2001-11-01 2002-11-01 治疗用的异喹啉化合物
CA002464342A CA2464342A1 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
JP2003540168A JP2005516896A (ja) 2001-11-01 2002-11-01 治療用のイソキノリン化合物
US10/494,424 US20070010526A1 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
MXPA04004076A MXPA04004076A (es) 2001-11-01 2002-11-01 Compuestos terapeuticos de isoquinolina.
RU2004112423/04A RU2004112423A (ru) 2001-11-01 2002-11-01 Терапевтические изохинолиновые соединения
HU0501089A HUP0501089A2 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
EP02780244A EP1451172A1 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
IL16151102A IL161511A0 (en) 2001-11-01 2002-11-01 Therapeutic isoquinoline compounds
KR1020047006593A KR20050042223A (ko) 2001-11-01 2002-11-01 치료용 이소퀴놀린 화합물
BR0213778-0A BR0213778A (pt) 2001-11-01 2002-11-01 Composição, método de tratamento de um ser humano ou animal que sofre de doenças, e, uso da composição
IS7236A IS7236A (is) 2001-11-01 2004-04-28 Meðferðarfræðileg ísókínólínefnasambönd
ZA200403240A ZA200403240B (en) 2001-11-01 2004-04-29 Therapeutic isoquinoline compounds.
CO04039910A CO5580832A2 (es) 2001-11-01 2004-04-30 Compuestos isoquinolina terapeuticos
NO20042154A NO20042154L (no) 2001-11-01 2004-05-25 Terapeutiske isokinolinforbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103644A SE0103644D0 (sv) 2001-11-01 2001-11-01 Therapeutic isoquinoline compounds

Publications (1)

Publication Number Publication Date
SE0103644D0 true SE0103644D0 (sv) 2001-11-01

Family

ID=20285846

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103644A SE0103644D0 (sv) 2001-11-01 2001-11-01 Therapeutic isoquinoline compounds

Country Status (18)

Country Link
US (1) US20070010526A1 (sv)
EP (1) EP1451172A1 (sv)
JP (1) JP2005516896A (sv)
KR (1) KR20050042223A (sv)
CN (1) CN1608061A (sv)
BR (1) BR0213778A (sv)
CA (1) CA2464342A1 (sv)
CO (1) CO5580832A2 (sv)
HU (1) HUP0501089A2 (sv)
IL (1) IL161511A0 (sv)
IS (1) IS7236A (sv)
MX (1) MXPA04004076A (sv)
NO (1) NO20042154L (sv)
PL (1) PL370058A1 (sv)
RU (1) RU2004112423A (sv)
SE (1) SE0103644D0 (sv)
WO (1) WO2003037887A1 (sv)
ZA (1) ZA200403240B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
JP2007501804A (ja) * 2003-08-08 2007-02-01 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7572805B2 (en) * 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
US7211585B2 (en) 2004-08-18 2007-05-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
ES2257167B1 (es) * 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Inhibidores del receptor 5-ht7.
EP1630158A1 (en) * 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
US7211584B2 (en) 2004-08-18 2007-05-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor ligands
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20140003484A (ko) * 2011-02-02 2014-01-09 아스테라스 세이야쿠 가부시키가이샤 테트라히드로이소퀴놀린 유도체
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
CA2858328A1 (en) * 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014028669A1 (en) * 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Novel compounds for modulation of ror-gamma activity
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9315464B1 (en) 2013-01-31 2016-04-19 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP7065951B2 (ja) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Pad阻害剤としての複素環式化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
KR20200131845A (ko) 2018-03-13 2020-11-24 주빌런트 프로델 엘엘씨 Pd1/pd-l1 상호작용/활성화 억제제로서의 비사이클릭 화합물
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
KR102589771B1 (ko) 2021-11-30 2023-10-17 엘지전자 주식회사 스크롤 압축기

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT689536E (pt) * 1993-03-16 2001-11-30 Pfizer Derivados de naftaleno
DE69417427T2 (de) * 1993-09-03 1999-11-25 Smithkline Beecham Plc Indol- und indolin-derivate als 5ht1d rezeptor antagonisten
FR2744450A1 (fr) * 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
JP2001506995A (ja) * 1996-12-19 2001-05-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー N−ピペラジン−1−イルフェニル−ベンズアミド誘導体
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
CN1309654A (zh) * 1998-07-20 2001-08-22 默克专利股份有限公司 联苯基衍生物
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
RU2004112423A (ru) 2005-10-10
EP1451172A1 (en) 2004-09-01
ZA200403240B (en) 2005-04-07
KR20050042223A (ko) 2005-05-06
US20070010526A1 (en) 2007-01-11
IL161511A0 (en) 2004-09-27
CO5580832A2 (es) 2005-11-30
WO2003037887A8 (en) 2005-03-17
BR0213778A (pt) 2004-11-09
CA2464342A1 (en) 2003-05-08
JP2005516896A (ja) 2005-06-09
WO2003037887A1 (en) 2003-05-08
IS7236A (is) 2004-04-28
PL370058A1 (en) 2005-05-16
MXPA04004076A (es) 2004-07-23
HUP0501089A2 (en) 2007-09-28
NO20042154L (no) 2004-07-29
CN1608061A (zh) 2005-04-20

Similar Documents

Publication Publication Date Title
SE0103644D0 (sv) Therapeutic isoquinoline compounds
SE0103649D0 (sv) Therapeutic quinoline compounds
SE0103648D0 (sv) Therapeutic quinolone compounds
WO2002055012A3 (en) Therapeutic heterocyclic compounds
WO2002055013A3 (en) Therapeutic chromone compounds
NZ514711A (en) Compounds useful as anti-inflammatory agents
MY135688A (en) Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
SG147472A1 (en) N-thiazol-2-yl-benzamide derivatives
ATE393123T1 (de) Herstellung von eisenverbindungen durch hydrothermale umwandlung
DE60130365D1 (de) Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
ATE282605T1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
SE0103647D0 (sv) Therapeutic chromone compounds
SE0103650D0 (sv) Therapeutic heterocyclic compounds
CA2411412A1 (en) Indole derivatives useful for the treatment of cns disorders
AU2002243419A1 (en) Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
DK1756066T3 (da) Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet
IL160615A0 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
ATE330605T1 (de) Piperidin-2,6-dionpamoat-salze und ihre verwendung zur behanldung von stressbedingten affektiven st rungen
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
NO20050146D0 (no) N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon
WO2002048105A3 (en) Aryloxy piperidinyl derivatives for the treatment of depression
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
DE602004005863D1 (de) 4-arylsulphonylpiperidin-derivate als 5-ht2a -rezeptor antagonisten
SI1603877T1 (sl) Novi derivati aminopiridina kot antagonisti mGiuR5
NO20026246D0 (no) 2-aminoalkyl-tieno[2,3-d]pyrimidiner